Ad hoc announcement pursuant to Art. 53 LR
Further study analysis reveals significant multi-domain benefits in PANSS and Clinical Global Impression of Change (CGI-C) ratings
Ad hoc announcement pursuant to Art. 53 LR
Primary endpoint and key secondary endpoint of study met; drug was well tolerated, with no safety concerns identified
Glutamatergic
Ad hoc announcement pursuant to Art. 53 LR
Milan, Italy, April 17, 2024, 11:30 am CET – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical
Data from study 014/015, a phase II trial evaluating evenamide as add-on therapy for patients with treatment-resistant schizophrenia (TRS) for up to one year
Presentation of study
Dear Newron Shareholder,
when presenting our Annual Report 2023, recently, we looked back at the significant progress Newron has made, last year: against a backdrop of challenging
Ad hoc announcement pursuant to Art. 53 LR
Milan, Italy, March 19, 2024, 07:00 am CET – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical
Ad hoc announcement pursuant to Art. 53 LR
EIB agrees to extend repayment dates of tranches one to three of its loan to the Company until end of 2025 and into 2026, after
Ad hoc announcement pursuant to Art. 53 LR
Proceeds of up to EUR 15.0* million
Milan, Italy, March 14, 2024, 17:45 CET – Newron Pharmaceuticals S.p.A. (“Newron”, or
Ad hoc announcement pursuant to Art. 53 LR
Treatment with evenamide demonstrated significant, clinically important, progressive, sustained and long-lasting improvement on PANSS
Ad hoc announcement pursuant to Art. 53 LR
290 patients participate at study centers in Europe, Asia and Latin America
Results from the study are expected in March 2024
The information on the following pages may be made available in the United States. By clicking on the link below, you agree that you are in the United States.
